Advertisement

Topics

BioTime, Inc. and Abcodia Ltd. Company Profile

23:40 EDT 23rd June 2018 | BioPortfolio

BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. BioTime’s focus is on pluripotent stem cell technology based on human embryonic stem (“hES”) cells and induced pluripotent stem (“iPS”) cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTime’s therapeutic and research products include a wide array of proprietary PureStem® progenitors, HyStem® hydrogels, culture media, and differentiation kits. BioTime is developing Renevia™ (a HyStem® product) as a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications, and is planning to initiate a pivotal clinical trial around Renevia™, in 2014. In addition, BioTime has developed Hextend®, a blood plasma volume expander for use in surgery, emergency trauma treatment and other applications. Hextend® is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ HealthCare Corporation, under exclusive licensing agreements.


News Articles [47 Associated News Articles listed on BioPortfolio]

BioTime erhält Zuschuss in Höhe von 1,9 Millionen US-Dollar für Weiterentwicklung von OpRegen für Dry-AMD

BioTime, Inc. (NYSE American: BTX), ein klinisches Biotechnologie-Unternehmen, das sich auf degenerative Erkrankungen spezialisiert, hat von der Israel Innovation Authority (IIA) für das Jahr 2018...

BioTime Announces $1.9 Million Grant for Continued Development of OpRegen for Dry-AMD

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has been awarded a new grant for 2018 of up to 6.9 million Israeli New Shekels (approxi...

BioTime to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference ...

Investor Contact:BioTimeDavid Nakasone, 510-871-4188Dnakasone@biotime.comorMedia Contact:JQA Partners, Inc.Jules Abraham, 917-885-7378jabraham@jqapartners.com Read more...

BioTime to Present at the 8th Annual LD Micro Invitational

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer of BioT...

BioTime to Participate at the BIO CEO and Investor Conference in New York, February 12th and 13th 2018

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Adi...

BioTime to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference in Fort Lauderdale, January 29, 2018

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Rus...

A Look At BioTime: Part 1 - Introduction And Renevia

BioTime's Dry AMD Product OpRegen: A Look At Trial Data

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [8 Associated Companies listed on BioPortfolio]

BioTime, Inc. and Abcodia Ltd.

BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell ...

BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell techn...

BioTime, Inc. 

BioTime is a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company’s current clinical ...

BioTime Incorporated

BioTime, Inc. (OTCBB: BTIM), based in Emeryville, California, is engaged in the research and development of aqueous-based synthetic solutions that may be used as plasma expanders, organ preservation s...

AgeX Therapeutics, Inc.

AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE MKT:BTX), is a biotechnology company applying technology relating to cell immortality and regenerative biology, to agi...

More Information about "BioTime, Inc. and Abcodia Ltd." on BioPortfolio

We have published hundreds of BioTime, Inc. and Abcodia Ltd. news stories on BioPortfolio along with dozens of BioTime, Inc. and Abcodia Ltd. Clinical Trials and PubMed Articles about BioTime, Inc. and Abcodia Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioTime, Inc. and Abcodia Ltd. Companies in our database. You can also find out about relevant BioTime, Inc. and Abcodia Ltd. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...


Corporate Database Quicklinks



Searches Linking to this Company Record